These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 30181272)
1. Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy. Ho PP; Lahey LJ; Mourkioti F; Kraft PE; Filareto A; Brandt M; Magnusson KEG; Finn EE; Chamberlain JS; Robinson WH; Blau HM; Steinman L Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9182-E9191. PubMed ID: 30181272 [TBL] [Abstract][Full Text] [Related]
2. The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice. Li N; Parkes JE; Spathis R; Morales M; Mcdonald J; Kendra RM; Ott EM; Brown KJ; Lawlor MW; Nagaraju K J Neuromuscul Dis; 2021; 8(s2):S325-S340. PubMed ID: 34569971 [TBL] [Abstract][Full Text] [Related]
3. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice. Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126 [TBL] [Abstract][Full Text] [Related]
5. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500 [TBL] [Abstract][Full Text] [Related]
6. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice. El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199 [TBL] [Abstract][Full Text] [Related]
8. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574 [TBL] [Abstract][Full Text] [Related]
9. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713 [TBL] [Abstract][Full Text] [Related]
10. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Bostick B; Yue Y; Lai Y; Long C; Li D; Duan D Hum Gene Ther; 2008 Aug; 19(8):851-6. PubMed ID: 18666839 [TBL] [Abstract][Full Text] [Related]
11. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067 [TBL] [Abstract][Full Text] [Related]
12. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Athanasopoulos T; Graham IR; Foster H; Dickson G Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965 [TBL] [Abstract][Full Text] [Related]